Objective:To compare the characteristics of gait disorders between patients with idiopathic normal pressure hydrocephalus(iNPH)and Parkinson's disease(PD)patients.Methods:General clinical data and gait assessment results of 16 iNPH patients, 20 PD patients, and 23 healthy adults seeking treatment at Tianjin Huanhu Hospital between January 2020 and December 2020 were retrospectively analyzed.Gait analysis was conducted using the Mobility Lab? system with APDM Opal sensors from the US.Results:The 16 patients in the iNPH group had a mean age of(68.81±8.73), the 20 patients in the PD group had a mean age of(65.05±10.15), and the 23 adults in the control group had a mean age of(59.96±6.20).There was no significant difference in age between the iNPH group and the PD group( P>0.05).However, the iNPH group was older than the healthy control group( t=3.71, P<0.05).The disease duration of the iNPH group was(22.94±23.19)months, which was shorter than(92.60±53.70)months in the PD group( t=5.23, P<0.05).The mini-mental state examination(MMSE)score(17.13±7.08)and the Montreal Cognitive Assessment(MoCA)score(11.75±5.43)of the iNPH group were significantly lower than those in the PD group[(24.17±4.73), t=3.45, P<0.05、(21.29±5.82), t=4.86, P<0.05]and the control group[(26.70±1.61), t=5.31, P<0.05、(22.78±3.30), t=7.89, P<0.05].Compared with the PD group, the iNPH group had a significantly lower foot clearance[right: (1.65±0.76)cm vs.(2.56±1.30)cm]and smaller bilateral toe-off angles[left: (20.59±6.11)° vs.(28.43±6.36)°; right: (20.78±6.88)° vs.(28.12±7.49)°, t=3.74、3.02, respectively, all P<0.05].There were statistically significant differences in all gait parameters in iNPH patients compared with the control group( P<0.05). Conclusions:iNPH patients exhibit clear gait disturbance, which is more prominent than in PD patients.The wearable gait analysis system can accurately assess gait disorders in iNPH patients, and can be applied to gait assessment and the development of rehabilitation plans.

Objective:To investigate the clinical application value of triamcinolone acetonide combined with hyaluronidase injection and shallow X-ray in the treatment of multiple keloids.Methods:From March 2018 to October 2019, 144 cases of multiple keloids in outpatient department were analyzed retrospectively. There were 89 males and 55 females, aged from 16 to 68, with an average age of 28 years. The average duration was 6 years(ranged from 1 to 20 years). Among them, 65 cases were treated with superficial X-ray radiotherapy combined with local injection (group A) and 79 cases were treated only with local injection (group B). The Vancouver Scar Scale (VSS), t-test and chi-square test were used to evaluate the validity of the two groups. The patients were followed up for 6-18 months. Results:In group A, the VSS was changed from 11.9±0.9 to 6.5±1.1. 51 cases were improved and 14 cases showed obviously effective. The significant effect rate was 21.54%(14/65). The main side effect of group A was transient pigmentation. In group B, the VSS was changed varied from 12.1±1.0 to 8.3±1.0. 74 cases were improved, 2 cases were markedly effective, but 3 cases were ineffective. The significant effective rate was 2.63%(2/76). The side effects include telangiectasia, skin atrophy, even arousing abnormal menstrual cycles and hair growth in several females. The comparability between the two groups was confirmed by the VSS scores before treatment( t=-1.114, P=0.267). Then, the difference of VSS scores became significant after treatment( t=-10.208, P<0.001), the same to apparent efficiency( χ2=12.450, P<0.001). Conclusions:Triamcinolone acetonide combined with hyaluronidase injection and shallow X-ray radiation therapy for multiple keloids has ideal curative effect and low incidence of adverse reactions, which is a prospected clinical method.

Objective:To investigate the clinical application value of triamcinolone acetonide combined with hyaluronidase injection and shallow X-ray in the treatment of multiple keloids.Methods:From March 2018 to October 2019, 144 cases of multiple keloids in outpatient department were analyzed retrospectively. There were 89 males and 55 females, aged from 16 to 68, with an average age of 28 years. The average duration was 6 years(ranged from 1 to 20 years). Among them, 65 cases were treated with superficial X-ray radiotherapy combined with local injection (group A) and 79 cases were treated only with local injection (group B). The Vancouver Scar Scale (VSS), t-test and chi-square test were used to evaluate the validity of the two groups. The patients were followed up for 6-18 months. Results:In group A, the VSS was changed from 11.9±0.9 to 6.5±1.1. 51 cases were improved and 14 cases showed obviously effective. The significant effect rate was 21.54%(14/65). The main side effect of group A was transient pigmentation. In group B, the VSS was changed varied from 12.1±1.0 to 8.3±1.0. 74 cases were improved, 2 cases were markedly effective, but 3 cases were ineffective. The significant effective rate was 2.63%(2/76). The side effects include telangiectasia, skin atrophy, even arousing abnormal menstrual cycles and hair growth in several females. The comparability between the two groups was confirmed by the VSS scores before treatment( t=-1.114, P=0.267). Then, the difference of VSS scores became significant after treatment( t=-10.208, P<0.001), the same to apparent efficiency( χ2=12.450, P<0.001). Conclusions:Triamcinolone acetonide combined with hyaluronidase injection and shallow X-ray radiation therapy for multiple keloids has ideal curative effect and low incidence of adverse reactions, which is a prospected clinical method.

Objective To explore the effect of motor imagery therapy combined with balance evaluation and training on balance and performance in the activities of daily living (ADL) after an initial stroke.Methods A total of 48 stroke patients were randomly divided into a control group (n =25) and an observation group (n =23).All of the patients in both groups were given routine rehabilitation and balance training.In addition,the patients of the observation group were given motor imagery therapy.Balance and ADL performance were assessed before the training and 2 weeks and 4 weeks after the training began.The subjects' balance was analyzed using the center of the gravity shift index,shift angle,total length of shift trace and envelope area using a balance evaluation system and the balance subscale of the Fugl-Meyer assessment (FM-B).Performance in the activities of daily living was assessed using the modified Barthel index (MBI).Results Before the training there were no significant differences between the two groups in terms of any of the measurements.After 2 weeks and 4 weeks of training,all the measurements in both groups were significantly better than those before training,but the improvement of the observation group was significandy greater than that of the control group (except in terms of the MBI).Conclusion Motor imagery therapy combined with balance training can distinctly improve the balance and activities of daily living of stroke survivors.The combination is worthy of application in the clinic.

OBJECTIVETo investigate the effect of CD59 gene inhibition mediated by RNA interference on the proliferation and apoptosis of non-small cell lung cancer (NSCLC) GLC-P cells in vitro.

METHODSRecombinant plasmids for RNA interference of CD59 gene were constructed and transfected into GLC-P cells via lipofectamine 2000. The stably transfected cells were examined with real-time RT-PCR, MTT assay and enzyme-linked immunosorbent assay to investigate the changes in cell proliferation and apoptosis.

RESULTSCompared with the control cells, the cells transfected with CD59-siRNA showed significantly decreased expression levels of CD59 mRNA (P<0.05) and significantly inhibited cell proliferation.

CONCLUSIONCD59 gene is highly expressed in NSCLC and RNA interference-mediated CD59 silencing can strongly inhibit the proliferation and induce apoptosis in GLC-P cells, which shed light on a potentially new target for targeted gene therapy of NSCLC.

Apoptosis ; CD59 Antigens ; genetics ; Carcinoma, Non-Small-Cell Lung ; pathology ; Cell Line, Tumor ; Cell Proliferation ; Enzyme-Linked Immunosorbent Assay ; Genetic Therapy ; Humans ; RNA Interference ; RNA, Messenger ; RNA, Small Interfering ; Transfection

Objective To investigate the effect of CD59 gene inhibition mediated by RNA interference on the proliferation and apoptosis of non-small cell lung cancer (NSCLC) GLC-P cells in vitro. Methods Recombinant plasmids for RNA interference of CD59 gene were constructed and transfected into GLC-P cells via lipofectamine 2000. The stably transfected cells were examined with real-time RT-PCR, MTT assay and enzyme-linked immunosorbent assay to investigate the changes in cell proliferation and apoptosis. Results Compared with the control cells, the cells transfected with CD59-siRNA showed significantly decreased expression levels of CD59 mRNA (P<0.05) and significantly inhibited cell proliferation. Conclusions CD59 gene is highly expressed in NSCLC and RNA interference-mediated CD59 silencing can strongly inhibit the proliferation and induce apoptosis in GLC-P cells, which shed light on a potentially new target for targeted gene therapy of NSCLC.

Objective To investigate the effect of CD59 gene inhibition mediated by RNA interference on the proliferation and apoptosis of non-small cell lung cancer (NSCLC) GLC-P cells in vitro. Methods Recombinant plasmids for RNA interference of CD59 gene were constructed and transfected into GLC-P cells via lipofectamine 2000. The stably transfected cells were examined with real-time RT-PCR, MTT assay and enzyme-linked immunosorbent assay to investigate the changes in cell proliferation and apoptosis. Results Compared with the control cells, the cells transfected with CD59-siRNA showed significantly decreased expression levels of CD59 mRNA (P<0.05) and significantly inhibited cell proliferation. Conclusions CD59 gene is highly expressed in NSCLC and RNA interference-mediated CD59 silencing can strongly inhibit the proliferation and induce apoptosis in GLC-P cells, which shed light on a potentially new target for targeted gene therapy of NSCLC.

OBJECTIVETo investigate the presence of miRNA-144 in the saliva of patients with esophageal cancer and its value for early diagnosis of esophageal cancer.

METHODSSaliva samples were collected form patients with esophageal cancer admitted in the Fourth Affiliated Hospital of Jinan University and the First Affiliated Hospital of Guangzhou Medical College between January, 2011 and May, 2013, with saliva samples from 50 middle-aged healthy volunteers matched for age and gender ratio as the control group. The contents of miRNA-144 in the samples were detected with RT-PCR.

RESULTSThe levels of miRNA-144 in both the whole saliva and saliva supernatant were significantly higher in esophageal cancer group than in the control group (P<0.05). In the whole saliva, the cut-off point of miRNA-144 was ≥100, with a sensitivity of 74.6% and a specificity of 92.0% for esophageal cancer diagnosis (Az=0.865); in saliva supernatant, the cut-off point was ≥20 with a sensitivity of 53.7% and a specificity of 94.0% (Az=0.754), suggesting a moderate diagnostic value of miRNA-144 in whole saliva and saliva supernatant.

CONCLUSIONmiRNA-144 is highly expressed in the saliva of patients with esophageal cancer and can be used as a genetic marker for early diagnosis of esophageal cancer.

Biomarkers, Tumor ; Early Diagnosis ; Esophageal Neoplasms ; diagnosis ; Humans ; MicroRNAs ; analysis ; Middle Aged ; Saliva ; chemistry ; Sensitivity and Specificity

Objective To investigate the presence of miRNA-144 in the saliva of patients with esophageal cancer and its value for early diagnosis of esophageal cancer. Methods Saliva samples were collected form patients with esophageal cancer admitted in the Fourth Affiliated Hospital of Jinan University and the First Affiliated Hospital of Guangzhou Medical College between January, 2011 and May, 2013, with saliva samples from 50 middle-aged healthy volunteers matched for age and gender ratio as the control group. The contents of miRNA-144 in the samples were detected with RT-PCR. Results The levels of miRNA-144 in both the whole saliva and saliva supernatant were significantly higher in esophageal cancer group than in the control group (P<0.05). In the whole saliva, the cut-off point of miRNA-144 was≥100, with a sensitivity of 74.6%and a specificity of 92.0%for esophageal cancer diagnosis (Az=0.865); in saliva supernatant, the cut-off point was ≥20 with a sensitivity of 53.7% and a specificity of 94.0%(Az=0.754), suggesting a moderate diagnostic value of miRNA-144 in whole saliva and saliva supernatant. Conclusion miRNA-144 is highly expressed in the saliva of patients with esophageal cancer and can be used as a genetic marker for early diagnosis of esophageal cancer.

Objective To investigate the presence of miRNA-144 in the saliva of patients with esophageal cancer and its value for early diagnosis of esophageal cancer. Methods Saliva samples were collected form patients with esophageal cancer admitted in the Fourth Affiliated Hospital of Jinan University and the First Affiliated Hospital of Guangzhou Medical College between January, 2011 and May, 2013, with saliva samples from 50 middle-aged healthy volunteers matched for age and gender ratio as the control group. The contents of miRNA-144 in the samples were detected with RT-PCR. Results The levels of miRNA-144 in both the whole saliva and saliva supernatant were significantly higher in esophageal cancer group than in the control group (P<0.05). In the whole saliva, the cut-off point of miRNA-144 was≥100, with a sensitivity of 74.6%and a specificity of 92.0%for esophageal cancer diagnosis (Az=0.865); in saliva supernatant, the cut-off point was ≥20 with a sensitivity of 53.7% and a specificity of 94.0%(Az=0.754), suggesting a moderate diagnostic value of miRNA-144 in whole saliva and saliva supernatant. Conclusion miRNA-144 is highly expressed in the saliva of patients with esophageal cancer and can be used as a genetic marker for early diagnosis of esophageal cancer.